Skip to main content
SpringerLink
Log in

Primary and Secondary Hypogonadism in Women

  • Chapter
Endocrine Replacement Therapy in Clinical Practice

Part of the book series: Contemporary Endocrinology ((COE))

  • 120 Accesses

Abstract

Hormone replacement in hypogonadal women is a highly effective preventive health care measure. Estrogen replacement results in a nearly 50% reduction in the risks of vertebral and hip fractures and alleviates menopausal symptoms. Hypogonadal symptomatology such as hot flushes, irritability, anxiety, mood disturbances, loss of libido, and genitourinary atrophy are reduced and often alleviated by estrogen replacement. Numerous estrogen formulations and delivery systems are now available. Progestogens are utilized in women with a uterus to reduce the risk of endometrial hyperplasia and endometrial cancer. The role of androgens and phytoestrogens in hormone replacement therapy (HRT) are noted. Dehydroepiandrosterone (DHEA) supplementation is reviewed. Risks and complications of HRT are outlined, including the potential risk of breast cancer, cardiovascular effects, and nuisance side effects. The expanding role of selective estrogen-receptor modulators (SERMs) is highlighted.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Hagstad A, Janson PO. The epidemiology of climacteric symptoms. ACTA Obstet Gynecol Scand 1986; 134: 59–65.

    CAS  Google Scholar 

  2. Keating NL, Cleary PD, Rossi AS, et al. Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med 1999; 130: 545–553.

    PubMed  CAS  Google Scholar 

  3. Seeman E Osteoporosis: trials and tribulations. Am J Med 1997;18;103:74S–87S.

    Google Scholar 

  4. Eiken F, Kolthoff N, Nielsen SF. Effect of 10 years’ hormone replacement therapy on bone mineral content in postmenopausal women. Bone 1996; 5 (Suppl): 191S - 193S.

    Google Scholar 

  5. Daly E, Roche M, Barlow D, Gray A, McPherson K, Vessey M. HRT: An analysis of benefits, risks and costs. Br Med Bull 1992; 48: 368–400.

    PubMed  CAS  Google Scholar 

  6. Van derLoos M, Paccaud F, GutzwillerF, Chrzanowski R. Impact of hormonal prevention on fractures of the proximal femur in postmenopausal women: a simulation study. Soz Praventivmed 1988; 33: 162–166.

    Google Scholar 

  7. Speroff L, Lobo RA. Postmenopausal hormone therapy and the cardiovascular system. Heart Dis Stroke 1994; 3: 173–176.

    PubMed  CAS  Google Scholar 

  8. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605–613.

    PubMed  CAS  Google Scholar 

  9. Herrington DM, Reboussin VN, Brosnihan KB, et al. Effects of estrogen replacement therapy on the progression of coronary-artery atherosclerosis. N Engl J Med. 2000; 343: 522–529.

    PubMed  CAS  Google Scholar 

  10. Clarke S, Kelleher J, Lloyd-Jones H, et al. Transdermal hormone replacement therapy for secondary prevention of coronary artery disease in postmenopausal women. Eur Heart J 2000; 21 (Suppl): 212.

    Google Scholar 

  11. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy opstmenopausal women. Principal results from the Women’s Heath initiative Randomized Controlled Trial. JAMA 2002; 288:321–333; L’ Enfant C. Preliminary trends in women’s health in the Women’s Health Initiative. National Heart, Lung, and Blood Institute Communications Office, Bethesda, MD, 2000.

    Google Scholar 

  12. Mansen JE. Postmenopausal hormone therapy and atherosclerotic disease. Am Heart J 1994; 128: 1337–1343.

    Google Scholar 

  13. Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 1998; 19: 55–72.

    PubMed  CAS  Google Scholar 

  14. Jorm AF, Korten AE, Henderson AS. The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatr Scand 1987; 76: 465–479.

    PubMed  CAS  Google Scholar 

  15. Paganini-Hill A, Henderson VW. Estrogen deficiency and risk of Alzheimer’s disease in women. Am J Epidemiol 1994; 140: 256–261.

    PubMed  CAS  Google Scholar 

  16. Paganini-Hill A, Henderson VW. Estrogen replacement therapy and risk of Alzheimer’s disease. Arch Intern Med 1996; 156: 2213–2217.

    PubMed  CAS  Google Scholar 

  17. Brenner De, Kukull WA, Stergachis A, et al. Postmenopausal estrogen replacement therapy and the risk of Alzheimer’s disease: a population-based case-control study. Am J Epidemiol 1994; 140: 262–267.

    PubMed  CAS  Google Scholar 

  18. Mortel KF, Meyers JS. Lack of postmenopausal estrogen replacement therapy and the risk of dementia. J Neuropsychiat Clin Neurosci 1996; 7: 334–337.

    Google Scholar 

  19. Kawas C, Resnick 5, Morrison A, et al. A prospective study of estrogen replacement therapy and the risk of development of Alzheimer’ s disease: the Baltimore Longitudinal Study of Aging. Neurology 1997; 48: 1517–1521.

    PubMed  CAS  Google Scholar 

  20. Grodstein F, Chen J, Pollend A, et al. Postmenopausal hormone therapy and cognitive function in healthy older women. J Am Geriatri Soc 2000; 48: 746–752

    CAS  Google Scholar 

  21. Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer’s disease: a randomized controlled trial: Alzheimer’s Disease Cooperative Study. JAMA 2000; 283: 1007–1015.

    PubMed  CAS  Google Scholar 

  22. Gould E, Wooley CS, Frankfurt M, McEwen BS. Gonadal steroids regulate dendritic spine density in hippocampal pyramidal cells in adulthood. J Neurosci 1990; 10: 1286–1291.

    PubMed  CAS  Google Scholar 

  23. Luine VN. Estradiol increases choline acetyltransferase activity in specific basal forebrain nuclei and projection areas of female rats. Exp Neurol 1985; 89: 484–490.

    PubMed  CAS  Google Scholar 

  24. Behl C, Davis JB, Lesley R, Schubert D. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 1994; 77: 817–827.

    PubMed  CAS  Google Scholar 

  25. Ravnikar VA. Compliance with hormone therapy. Am J Obstet Gynecol 1987; 156: 1332–1334.

    PubMed  CAS  Google Scholar 

  26. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of post menopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000; 133: 933–941.

    PubMed  CAS  Google Scholar 

  27. Chae CU, Manson JE. Postmenopausal hormone replacement therapy. In: Hennekens CH, ed. Clinical Trials in Cardiovascular Disease: A Companion to Braunwald’s Heart Disease. Saunders, Philadelphia, 1999, pp. 399–414.

    Google Scholar 

  28. Pstay BM, Smith NL, LeMaitre RN, et al. Hormone replacement therapy prothrombotic mutations and the risk of incident non-fatal myocardial infarctions in postmenopausal women. JAMA 2001; 285: 906–913.

    Google Scholar 

  29. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995; 85: 304–313.

    PubMed  CAS  Google Scholar 

  30. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Intervention (PEPI) Trial. JAMA 1995; 273: 199–208 (with Erratum, JAMA 1995;274:1676).

    Google Scholar 

  31. Grady D, Wenger NK, Herrington D, et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease: the heart and estrogen/progestin replacement study (HEPRS). Ann Intern Med 2000; 132: 689–696.

    PubMed  CAS  Google Scholar 

  32. The Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from fifty-one epidemiologic studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997; 350: 1047–1059.

    Google Scholar 

  33. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogenprogestin replacement therapy in breast cancer risk. JAMA 2000; 283: 485–491.

    PubMed  CAS  Google Scholar 

  34. Rodriguez C, Patel AV, Calle E, et al. Estrogen replacement therapy in ovarian cancer mortality in a larger prospective study of US women. JAMA 2001; 285: 1460–1465.

    PubMed  CAS  Google Scholar 

  35. Garg PP, Kerlikoeske K, Subak L, et al. Hormone replacement therapy in the risk of epithelial ovarian carcinoma: a meta-analysis. Obstet Gynecol 1998; 92: 472–479.

    PubMed  CAS  Google Scholar 

  36. Coughlin SS, Giutozzi A, Smith SJ, et al. A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer. J Clin Epidemiol 2000; 53: 367–375.

    PubMed  CAS  Google Scholar 

  37. Negri E, Tzonou A, Beral V, et al. Hormone therapy for menopause and ovarian cancer in a collaborative reanalysis of European studies. Int J Cancer 1999; 80: 848–851.

    PubMed  CAS  Google Scholar 

  38. Jordan CV. Estrogen receptor antagonists. In: Adashi EY, Rock JA, , eds. Reproductive Endocrinology, Surgery, and Technology. Lippencott-Raven, Philadelphia, PA, 1996, p. 535.

    Google Scholar 

  39. Mashchak CA, Lobo RA, Dozono-Takano R, et at. Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obstet Gynecol 1982; 144: 511–518.

    PubMed  CAS  Google Scholar 

  40. Eighth Supplement to U.S.P. XXII. Easton, PA. Mack; 1990; 3256–3258.

    Google Scholar 

  41. Lobo RL, Nguyen HN, Eggena P, Brenner PF. Biologic effects of equilin sulfate in postmenopausal women. Fertil Steril 1988; 49: 234–238.

    PubMed  CAS  Google Scholar 

  42. Brosnihan KB, Weddle D, Anthony MS, Heise C, Li F, Ferrano CM. Effects of chronic hormone replacement on the renin-angiotensin system in cynomolgus monkeys. J Hypertens 1997; 15: 719–726.

    PubMed  CAS  Google Scholar 

  43. Aylward M, Maddock J, Rees PL. Natural estrogen replacement therapy and blood clotting. Br Med J 1976; 1: 220–222.

    PubMed  CAS  Google Scholar 

  44. Varma TR. Effect of estrogen replacement on blood coagulation factors in postmenopausal women. Int J Gynaecol Obstet 1983; 21: 291–296.

    PubMed  CAS  Google Scholar 

  45. Perez-Gutthan. Hormone replacement therapy and risk of venous thromboembolism: a population-based case controlled study. BMJ 1997; 314: 796–800.

    Google Scholar 

  46. Wash Drug Lett. 1991:6.

    Google Scholar 

  47. Bhavnani BR. Pharmacokinetics and pharmacodynamics of conjugated equine, estrogens: chemistry and metabolism. Proc Soc Exp Biol Med 1998; 217: 6–16.

    PubMed  CAS  Google Scholar 

  48. Yen SCC, Martin FL, Burnier AM, et at. Circulating estradiol, estrone, and gonadotropin levels following the administration of orally active 17 beta estradiol in post-menopausal women. J Clin Endocrinol Metab 1975; 40: 518–521.

    PubMed  CAS  Google Scholar 

  49. Ryan KJ. Engel LL. Endocrinology 1953; 52: 287.

    PubMed  CAS  Google Scholar 

  50. LoboRA, Cassidenti DL. Pharmacokinetics of oral 17 beta estradiol. J Reprod Med 1992; 37: 77–84.

    PubMed  CAS  Google Scholar 

  51. Kuhl H. Pharmacokinetics of oestrogens and progestogens. Maturitas 1990; 12: 171–197.

    PubMed  CAS  Google Scholar 

  52. McEvoy GK, et al., eds. American Hospital Formulary Service. American Society of Hospital Pharmacists, Bethesda, MD, 1991.

    Google Scholar 

  53. Orme M, Back DJ, Ward S, Green S. The pharmacokinetics of ethinyl estradiol in the presence and absence of gestodene and desogestrel. Contraception 1991; 43: 305–316.

    PubMed  CAS  Google Scholar 

  54. Mandel FP, Geoia Fl, Lu KH, Biologic effects of various doses of ethinyl estradiol in postmenopausal women. Obstet Gynecol J 982; 59: 673–679.

    Google Scholar 

  55. Hammond CB, Maxon WS. Estrogen replacement therapy. Clin Obstet Gynecol 1986; 29: 407–430.

    PubMed  CAS  Google Scholar 

  56. Bewley S, BewleyTH. Drug dependence with estrogen replacement therapy. Lancet 1992; 339: 290, 291.

    Google Scholar 

  57. Kuiper GGJM, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson J-A.Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996; 93: 5925–5930.

    PubMed  CAS  Google Scholar 

  58. Mosselman S, Polman J, Dijkema R.ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett 1996; 392: 49–53.

    PubMed  CAS  Google Scholar 

  59. Gambrel RD Jr. Use of progestogen therapy. Am J Obstet Gynecol 1987; 156: 1304–1313.

    Google Scholar 

  60. Persson I. Cancer risk in women receiving estrogen-progestin replacement therapy. Maturitas 1996; 23: S37 - S45.

    PubMed  CAS  Google Scholar 

  61. Persson I, Thurfjell E, Bergstrom R, Holmberg L. Hormone replacement therapy and the risk of breast cancer. Nested case-control study in a cohort of Swedish women attending mammography screening. Int J Cancer 1997; 72: 758–761.

    PubMed  CAS  Google Scholar 

  62. von Schoultz B. HRT and breast cancer risk, what to advise? Eur J Obstet Gynecol Reprod Biol 1997; 71: 205–208.

    Google Scholar 

  63. Persson I, et al. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy: long-term follow-up of a Swedish cohort. Int J Cancer 1996; 67: 327–332.

    PubMed  CAS  Google Scholar 

  64. Caldas GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, Hennekens C, Rosner B, Speizer FE. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332: 1589–1593.

    Google Scholar 

  65. Colditz GA, Egan KM, Stampfer MJ. Hormone replacement therapy and risk of breast cancer: results from epidemiologic trials. Am J Obstet Gynecol 1993; 168: 1473–1480.

    PubMed  CAS  Google Scholar 

  66. Grodstein F, Stampfer MJ, Caldas GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997; 336: 1769–1775.

    PubMed  CAS  Google Scholar 

  67. Scarier C, Adami HO, Hoover R, Persson I. Cause-specific mortality in women receiving hormone therapy. Epidemiology 1997: 1: 59–65.

    Google Scholar 

  68. Peterson CM. Progestogens, progesterone antagonists, progesterone and androgens: Synthesis, classification, and uses. Clin Obstet Gynecol 1995; 38: 813–820.

    Google Scholar 

  69. Moyer DL, de Lignieres B, Driguez P, Fez JP. Prevention of endometrial hyperplasia by progesterone during long term estradiol replacement: influence of bleeding pattern and secretory changes. Fertil Steril 1993; 59: 992–997.

    PubMed  CAS  Google Scholar 

  70. The Writing Group for the PEPI Trial. Effects of estrogen and estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the postmenopausal estrogen/progestin interventions (PEPI). JAMA 1995; 273: 199–208.

    Google Scholar 

  71. Gillet JY, Andre G, Fauger B, Erny R, Buvat-Herbaut MA, et al. Induction of amenorrhea during hormone replacement therapy optimal micronized progesterone dose. A multicenter study. Maturitas 1994; 19: 103–116.

    PubMed  CAS  Google Scholar 

  72. Miles RA, Paulson RJ, Lobo RA, Press MF, Dahmoush L, Sauer MV. Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a cornparative study. Fertil Steril 1994; 62: 485–490.

    PubMed  CAS  Google Scholar 

  73. Casanas-Roux F, Nisolle M, Marbaix E, Smets M, Bassil 5, Donnez J. Morphometric, immunohistological and three-dimensional evaluation of the endometrium of menopausal women treated by oestrogen and Crinone, a new slow-release vaginal progesterone. Hum Reprod 1996; 11: 357–363.

    CAS  Google Scholar 

  74. Jensen J, Riis BJ, Strin V, Nilas L, Christiansen C. Long term effects of percutaneous estrogens and oral progesterone on serum lipoproteins in postmenopausal women. Am J Obstet Gynecol 1987; 156: 66–71.

    PubMed  CAS  Google Scholar 

  75. Shangold MM, Tomai TP, Cook JD, Jacobs SL, Zinaman MJ, Chin SY, Simon JA. Factors associated with withdrawal bleeding after administration of oral micronized progesterone in women with secondary amenorrhea. Fertil Steril 1991; 56: 1029–1033.

    Google Scholar 

  76. Whitehead MI, HillardTC, CrookD. The role and use of progestogens. Obstet Gynecol 1990; 75: 559–576.

    Google Scholar 

  77. Woodruff JD, Pickar JH for The Menopause Study Group. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens with medroxyprogesterone acetate or conjugated estrogens alone. Am J Obstet Gynecol 1994; 170: 1213.

    PubMed  CAS  Google Scholar 

  78. Ulrich LG, Barlow DH, Sturdee DW, Wells M, Campbell Mi, Nielsen B, Bragg AJ, Vessey MP. Quality of life and patient preference for sequential versus continuous combined HRT: the UK Kliofem multicenter study experience. UK Continuous Combined HRT Study Investigators. Int J Gynaecol Obstet 1997; 59: S11 - S17.

    PubMed  CAS  Google Scholar 

  79. Piegsa K, Calder A, Davis JA, McKay-Hart D, Wells M, Bryden F. Endometrial status in postmenopausal women on long-term continuous combined hormone replacement therapy (Kliofem). A comparative study of endometrial biopsy, outpatient hysteroscopy and transvaginal ultrasound. Eur J Obstet Gynecol Reprod Biol 1997; 72: 175–180.

    PubMed  CAS  Google Scholar 

  80. Leather AT, Savvas IA, Studd JWW. Endometrial histology and bleeding patterns after eight years of continuous combined estrogen and progestogen therapy in postmenopausal women. Obstet Gynecol 1991; 78: 1008–1010.

    PubMed  CAS  Google Scholar 

  81. Darj F, Nilsson S, Axelsson O, et al. Clinical and endometrial effects of estradiol and progesterone in postmenopausal women. Maturitas 1991; 13: 109–115.

    PubMed  CAS  Google Scholar 

  82. Gambrell RD Jr. Progestogens in estrogen-replacement therapy. Clin Obstet Gynecol 1995; 38: 890–901.

    PubMed  Google Scholar 

  83. Casper RF, Chapdelaine A. Estrogen and interrupted progestin: a new concept for menopausal replacement therapy. Am J Obstet Gynecol 1993; 168: 1188–1196.

    PubMed  CAS  Google Scholar 

  84. Judd HL, Judd GE, Lucas WF, Yen S.S. Endocrine function of the postmenopausal ovary: concentration of androgens and estrogens in ovarian and peripheral vein blood. J Clin Endo Metab 1974; 39: 1020–1024.

    CAS  Google Scholar 

  85. Vermilion A. The hormonal activity of the postmenopausal ovary. J Clin Endo Metab 1976; 42: 247–252.

    Google Scholar 

  86. Furuhjelm M, Karlgren F, Carstrom K. The effect of estrogen therapy on somatic and psychical symptoms in postmenopausal women. Acta Obstet Gynecol Scand 1984; 63: 655–661.

    PubMed  CAS  Google Scholar 

  87. Wallem K, Goy RW. Effects of estradiol benzoate, estrone, and proprionates of testosterone or dihydrotestosterone on sexual and related behaviors of ovariectomized rhesus monkeys. Horm Behav 1977; 9: 228–248.

    Google Scholar 

  88. Michael RP, Zumpe D. Effects of androgen administration on sexual invitations by female rhesus monkeys. Anim Behav 1977; 25: 936–944.

    PubMed  CAS  Google Scholar 

  89. Michael RP, Richter MC, Cain IA, et al. Artificial menstrual cycles, behavior and the role of androgens in female rhesus monkeys. Nature 1978; 175: 439–440.

    Google Scholar 

  90. Michael RP, Zumpe D, Keverne EB, et al. Neuroendocrine factors in the control of primate behavior. Rec Frog Horm Res. 1972; 28: 665–706.

    CAS  Google Scholar 

  91. Sherwin BB, Gelfand MM, Brender W. Androgen enhances sexual motivation in females: a prospective, crossover study of sex steroid administration in the surgical menopause. Psychosom Med 1985; 47: 339–351.

    PubMed  CAS  Google Scholar 

  92. Sherwin BB, Gelfand MM. The role of androgen in the maintenance of sexual functioning in oophorectomized women. Psychosom Med 1987; 49: 397–409.

    PubMed  CAS  Google Scholar 

  93. Sherwin BB, Gelfand MM. Differential symptoms response to parenteral estrogen and/or androgen administration in the surgical menopause. Am J Obstet Gynecol 1985, 151: 153–160.

    PubMed  CAS  Google Scholar 

  94. Young R, Wilta B, Dabbs I, et al. Comparison of estrogen plus androgen and estrogen on libido and sexual satisfaction in recently oophorectomized women. North American Menopause Society Meeting, September 17–20, 1992.

    Google Scholar 

  95. Dow MTG, Hart DM. Hormonal treatments of sexual unresponsiveness in postmenopausal women. Br J Obstet Gynaecol 1983; 90: 361–366.

    PubMed  CAS  Google Scholar 

  96. Sherwin BB, Gelfand MM. Sex steroids and affect in “the surgical menopause: a double blind, crossover study. Psychoneuroendocrinology 1985; 10: 325–335.

    PubMed  CAS  Google Scholar 

  97. Myers LS, Dixon J, Morrissette M, Carmichael M, Davidson JM. Effects of estrogen, androgen, and progestin on sexual psychophysiology and behavior in postmenopausal women. J Clin Endo Metab 1990; 70: 1124–1131.

    CAS  Google Scholar 

  98. Notelovitz M, Watts N, Timmons MC, et al. Effects of estrogen plus low dose androgen versus estrogen alone on menopausal symptoms in oophorectomized-hysterectomized women. North American Menopausal Society Meeting, September 17–20, 1992.

    Google Scholar 

  99. Colvard DS, Erickson, EF, Meeting FE et al, Identification of androgen receptors in normal human osteoblast-like cells. Proc Natl Acad Sci USA 1989; 86: 854–857.

    PubMed  CAS  Google Scholar 

  100. Kasperk CH, Wergedeal JE, et al. Androgens directly stimulate proliferation of bone cells in vitro. Endocrinology 1989; 124: 1576, 1577.

    Google Scholar 

  101. Kasperk C, Fitzsimmons R, Strong D, et al. Studies of the mechanism by which androgens enhance mitogenesis and differentiation in bone cells. J Clin Endocrinol Metab 1990; 71: 1322–329.

    PubMed  CAS  Google Scholar 

  102. Need AG, Horowitz M, Bridges A, Morris H, Nordic BE. Effects of nandrolonedecanoate and antiresorptive therapy on vertebral density in osteoporotic, postmenopausal women. Arch Am Med 1989; 149: 57–60.

    CAS  Google Scholar 

  103. Raisz LG, Wiita B, Artis A, et al. Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women. J Clin Endocrinol Metab 1995; 81: 37–43.

    Google Scholar 

  104. Smith EP, Boyd I, Frank GR, et al. Estrogen resistance caused by a mutation in the oestrogen-receptor gene in a man. N Engl J Med 1994; 331: 1056–1061.

    PubMed  CAS  Google Scholar 

  105. Savvas M, Studd JWW, Fogelman I, et al. Skeletal effects of oral oestrogen compared with subcutaneous oestrogen and testosterone in postmenopausal women. Br Med J 1988; 297: 331–333.

    CAS  Google Scholar 

  106. Savvas M, Studd JWW, Norman S, et al. Increase in bone mass after one year of percutaneous oestradiol and testosterone implants in post-menopausal women who have previously received longterm oral oestrogens. Br J Obstet Gynaecol 1992; 757–760.

    Google Scholar 

  107. Davis SR. McCloud F, Strauss BJG, Burger HG. Testosterone enhances estradiol effects on postmenopausal bone density and sexuality. Maturitas 1995; 21: 227–236.

    PubMed  CAS  Google Scholar 

  108. Garnet T, Studd, J, Watson N, Savvas M. The effects of plasma estradiol levels on increases in vertebral and femoral bone density following therapy with estradiol and estradiol with testosterone implants. Obstet Gynecol 1992; 79: 968–972.

    Google Scholar 

  109. Urman B, Pride SM, Ho Yeun BH. Elevated serum testosterone, hirsutism, and virilism associated with combined androgen-estrogen hormone replacement therapy. Obstet Gynecol 1991; 77: 595–598.

    PubMed  CAS  Google Scholar 

  110. Hickok LR, Toomey C, Speroff L. A comparison of esterified estrogens with and without methyltestosterone: effects on endometrial histology and serum lipoproteins in postmenopausal women. Obstet Gynecol 1993; 82: 924–927.

    Google Scholar 

  111. Gelfand MM, Wiita B. Int J Fertil Menopausal Stud 1996; 41: 412–422.

    Google Scholar 

  112. Phillips F, Bauman C. Safety surveillance of esterified estrogens-methyltestosterone (Estratest and Estratest HS) replacement therapy in the United States. Clin Ther 1997; 19: 1070–1084.

    PubMed  CAS  Google Scholar 

  113. Arjmandi BH, Alkel L, Hollis BW, Amin D, Stacewicz-Sapuntzakis M, Guo P, Kukreja SC. Dietary soybean protein prevents bone loss in an ovariectomized rat model of osteoporosis. J Nutr 21 1996; 126: 161–167.

    CAS  Google Scholar 

  114. Jayo MI, Anthony MS, Register TC, Rankin SE, Vest T, Clarkson TB. Dietary soy isoflavones and bone loss: a study in ovariectomized monkey. J Bone Miner Res 1996; 11: 8228.

    Google Scholar 

  115. Anthony MS, Clarkson TB, Hughes CL, Morgan TM, Burke CL. Soybean isoflavones improve cardiovascular risk factors without affecting reproductive system of peripubertal rhesus monkeys. J Nutr 1996; 126: 43–50.

    PubMed  CAS  Google Scholar 

  116. Anthony MS, Burke GL, Hughes CL, Clarkson TB. Does soy supplementation improve coronary heart disease risk? Circulation 1995; 91: 925–929.

    Google Scholar 

  117. Anthony MS, Clarkson TB, Hughes CL. Plant and mammalian estrogen effects on plasma lipids of female monkeys. Circulation 1994; 90: 1235–1239.

    Google Scholar 

  118. Williams 1K, Honore EK, Washburn SA, Clarkson TB. Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys. J Am Coll Cardiol 1994; 24: 1757–1761.

    Google Scholar 

  119. Messina MI, Persky V, Setchell KDR, Barnes S. Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr Cancer I 994; 21: 113–131.

    Google Scholar 

  120. Lu U, Anderson KE, Grady JJ, Nagamani M. Effects of soya consumption for one month on steroid hormones in premenopausal women: implications for breast cancer risk reduction. Cancer Epidemiol Biomarkers Prey 1996; 5: 63–70.

    CAS  Google Scholar 

  121. Knight DC, Eden IA. Areview of the clinical effects of phytoestrogens. Obstet Gynecol 1996; 87: 897–904.

    PubMed  CAS  Google Scholar 

  122. Orentreich N, Brind I, Rizer R, Vogelmen J. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentration throughout adulthood. J Clin Endocrinol Metab 1984; 59: 551–555.

    PubMed  CAS  Google Scholar 

  123. Nestler JE, Barlascini CO, Clore JN, Blackard WG. Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men. J Clin Endocrinol Metab 1988; 66: 57–61

    PubMed  CAS  Google Scholar 

  124. Barrett-Conner F, Khaw KT. Absence of an inverse relation of dehydroepiandrosterone sulfate with cardiovascular mortality in postmenopausal women. N Engl J Med 1987; 317: 711–715.

    Google Scholar 

  125. Casson PR, Buster IE. DHEA administration to humans: panacea or palaver? Sem Repro Endo 1995; 13: 247–256.

    Google Scholar 

  126. Casson PR, Anderson RN, Herod HG. Oral dehydroepiandrosterone in physiologic doses modulates immune function in postmenopausal women. Am J Obstet Gynecol 1993; 169: 1536–1539.

    PubMed  CAS  Google Scholar 

  127. Khorramo, Vu L, Yen SS. Activation of immune function by dehydroepiandrosterone (DHEA) in age-advanced men. J Gerontol 1997; 52: M1–7.

    Google Scholar 

  128. Buster IF, Casson PR, Stroaughn AB, et al. Postmenopausal steroid replacement with micronized dehydroepiandrosterone: preliminary oral bioavailability and dose proportionnality studies. Am J Obstet Gynecol 1992; 166: 1163–1168.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Daren A. Watts MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Howard T. Sharp MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Matthew Peterson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Endocrinology, Diabetes and Metabolism, Department of Medicine and Pathology, University of Utah School of Medicine and ARUP Laboratory, Salt Lake City, UT, USA

    A. Wayne Meikle MD

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

Watts, D.A., Sharp, H.T., Peterson, C.M. (2003). Primary and Secondary Hypogonadism in Women. In: Meikle, A.W. (eds) Endocrine Replacement Therapy in Clinical Practice. Contemporary Endocrinology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-375-0_25

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-375-0_25

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-416-6

  • Online ISBN: 978-1-59259-375-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation